171 Views

Truveris nets $12.75 mln Series C

Truveris said Friday that it has closed $12.75 million in Series C funding. Canaan Partners led the round with participation from return backers New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round. Based in New York City, Truveris is a platform for pharmacy pricing and benefits analysis.

107 Views

QPID Health nets $12.3 mln Series B funds

QPID Health said Tuesday that it has raised $12.3 million in Series B funding. New Leaf Venture Partners led the round. In conjunction with the funding, Philippe Chambon, managing director at New Leaf Venture Partners, has been added to QPID Health’s board of directors. Headquartered in Boston, QPID Health is a provider of clinical intelligence to healthcare providers.

124 Views

Boston biotech firm Intarcia snags $200 mln

Boston-based biotech company Intarcia Therapeutics has raised $200 million financing. RA Capital led the round with participation from investors that include Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners and Quilvest.

126 Views

VC-backed Versartis raises $126 mln for IPO

Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “VSAR.” Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.

CardioKinetix Completes $48 Million Series E Round

CardioKinetix, a Menlo Park, Calif.-based medical device company, has completed the $23 million second-tranche of its Series E financing, bringing the total round to $48 million. Panorama Capital is the company’s newest investor. It joins previous investors U.S. Venture Partners, JPMorgan Partners, New Leaf Venture Partners, SV Life Sciences, H&Q Healthcare Investors, and H&Q Life Sciences Investors.

Versartis Closes Series C Financing

Versartis, an emerging biotechnology company has completed a $25 million Series C financing lead by new investor Aisling Capital. Also participating in the round were existing investors Index Ventures, New Leaf Venture Partners and Advent Venture PartnersAdvent Life Sciences fund.

Principia Biopharma Inks $12.5M

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

Awarepoint Picks up $14M

Awarepoint Corp., the real-time location system services provider for healthcare clients, has added $14 million in funding. Heritage Group led the round and was joined by Kleiner Perkins Caufield & Byers, Cardinal Partners, Venrock, Jafco Ventures, Avalon Ventures, New Leaf Venture Partners and Top Tier Capital Partners. PRESS RELEASE: Awarepoint Raises $14 Million in Additional […]

CardioKinetix Appoints Veteran Medical Device Exec

Medical device company CardioKinetix has apointed Maria Sainz as president and chief executive officer. Recently Sainz served as general manager of Stryker Neurovascular, which acquired Concentric Medical in October 2011 under her leadership as president and CEO. CardioKinetix is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, Panorama Capital, and H&Q […]

Truveris Inks $10M Series B

Truveris Inc. has raised $10 million in Series B financing, the company announced Thursday. New Leaf Venture Partners led the round, which also included participation from Tribeca Venture Partners, New Atlantic Ventures and First Round Capital. Formed in 2009, Truveris makes software designed to provide transparency and cost containment in the prescriptions claims process. PRESS […]

Biogen Buys VC-Backed Stromedix

Publicly traded Biogen Idec is buying venture-backed Stromedix Inc. Under the terms of the deal, Biogen Idec will make an upfront cash payment of $75 million and additional payments of up to $487.5 million based on certain milestones. Stromedix’s investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and […]

CardioKinetix Seals $44M For Medical Devices

CardioKinetix, a medical device company developing transcatheter implants, has raised $44 million in a two-tranche Series E financing. New investors SV Life Sciences and New Leaf Venture Partners led the round, which included return backers including U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors. The company’s device, dubbed Parachute, is implanted into the left ventricle of the heart in a simple catheter lab procedure and is intended to treat patients with heart failure resulting from a myocardial infarction or heart attack.

Neuronetics Nets $30M Series E

Neuronetics, the Pennsylvania-based maker of non-invasive, non-systemic treatments for depression, completed a $30 million Series E financing. New investors Polaris Venture Partners and Pfizer Venture Investments led the round and were joined by previous investors Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures, and Onset Ventures.

Synageva Adds $25M in Financing

Lexington, Mass.-based Synageva BioPharma Corp. has closed on $25 million in new financing. No details of the financing were disclosed. Synageva has raised more than $70 million in the last two years from investors including New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson and Four Partners.

Versartis Closes $21M Series B

Mountain View, Calif.-based biotech company Versartis Inc., which is developing therapeutics to treat endocrine disorders, has raised $21 million in funding. New Leaf Venture Partners led the Series B round, which included participation from Advent Venture Partners’ Advent Life Sciences fund and existing shareholders Index Ventures and Amunix. The money will help Versartis conduct clinical trials of its product for growth hormone deficiency.

Confirmed: Chimerix’s $45 Million Fundraising

As peHUB.com reported late last week, Chimerix Inc., the pharmaceutical drug company working on orally-available antiviral therapeutics has completed a $45 million fundraising. New investors include Pappas Ventures and Morningside Group; other investors include Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

PEHUB Community

Join the 12503 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget